Skip to main content
CNC logo

CNC · Centene Corp

Track CNC — free
$73.92 -0.86 (-1.14%)
Market Cap
$37.02B
Shares
495.07M
Volume · Nov 17 633.95K Avg daily vol (3M) 4.88M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$74.77 Open$74.04 Day$73.93–75.97 52W close$31.80–76.01 Avg vol 30d5.4M Short int10.5M · 2.1% of shares · 2.0d Short vol40% Last earningsOct 27, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 27

Up next

Feb 5, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Oct 27
Earnings call
Q3 2026 earnings call

Centene reported third quarter adjusted diluted earnings per share of $0.58, ahead of expectations, and raised its 2026 outlook to greater than $5.20 per diluted share from greater than $4.80, supported by Medicare strength and Marketplace margin improvement.

Oct 27
Current report 8-K
Financial results

Centene Corporation reported third-quarter 2026 GAAP loss per share of $(0.14), adjusted diluted EPS of $0.58 and HBR of 92.7%. It raised 2026 GAAP diluted EPS guidance to greater than $3.46 and adjusted diluted EPS guidance to greater than $5.20.

Oct 27
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Centene reported third-quarter 2026 revenue growth of 2%, while membership fell 2.3 million, operating cash flows used $3.7 billion, GAAP diluted loss per share was $(0.14), and adjusted diluted EPS was $0.58.

Revenue $50.65B ▲ 1.9% Net loss $71M Diluted EPS -$0.14
Read from the MD&A section
Oct 8
Current report 8-K
Other events

Centene Corporation delivered notice on October 8, 2026 to redeem all $568,664,000 principal amount of its 4.25% Notes due December 15, 2027 on October 23, 2026, at 100% plus accrued interest, leaving no such notes outstanding.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$203.90B
Trailing 12 months
Net income (TTM)
$1.46B
Trailing 12 months
Revenue growth YoY
+1.9%
Year over year
Operating margin
0.5%
Trailing 12 months
P / E (TTM)
23.7
Trailing earnings · reciprocal yield 4.2%
FCF yield
11.2%
TTM · current market cap
Return on invested capital
5.4%
Trailing 12 months
Net cash
$8.04B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.6%
Year over year · more shares
Price change (1Y)
+97.5%
Trailing year
Short interest
2.1%
Latest settlement · 2.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 27, 2026
Q3 FY26

TL;DR. Centene reported better-than-expected Q3 adjusted diluted EPS of $0.58, raised 2026 adjusted EPS guidance to greater than $5.20 from greater than $4.80, improved its full-year HBR outlook, reduced debt, and expects adjusted EPS to grow in 2027. Risks include Medicaid membership attrition and rate-acuity pressure, Marketplace membership attrition, lower Medicare Advantage membership, a PDP margin reset, and enterprise optimization costs.

Bullish
  • + The full-year 2026 HBR midpoint improved by 15 basis points to 90.75%. new
  • + Marketplace is expected to deliver a full-year pre-tax margin at the top of its previous 4.5% to 5% range. new
  • + Debt fell by $1.1 billion since June 30, 2026, including full redemption of the 2027 Senior Notes in October. new
Bearish
  • − Medicaid membership is expected to decline 8% to 9% in 2026, with a larger Q4 step-down and associated acuity pressure. new
  • − Q3 produced a GAAP diluted loss per share of $(0.14). new
  • − Enterprise optimization produced $276 million of severance costs and $35 million of third-party vendor costs in Q3. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +32%
above
Price vs 50-day avg +11%
above
RSI (14) 62
neutral
MACD trend Positive
52-week position 97%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +9%
trailing
6-month return +27%
trailing
YTD return +82%
this year
Relative strength +29%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $67 › 200d $57 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +170 funds added
Insider flow Distributing
Net -$3.8M over 90 days · 100% sells
Short interest Falling
2.12% of shares out · ▼ -3.9% MoM · 2.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,070 holders — near 3-yr high, broad support
Squeeze score 55
elevated · 0–100
Fundamentals
Fair
Revenue growth +19%
Y/Y
Gross margin 7%
contracting
EPS growth −314%
Y/Y
Free cash flow $4.3B
Valuation P/E 24.8
rich
Buyback $1.8B
remaining
Balance sheet $487.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 46%
annualized · 1-yr
Max drawdown −33%
past year
ATR 4.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the 8-K filed Jul 28, 2026
Total revenues · Full Year 2026 $193.5B – $197.5B
prior FY $194.78B midpoint +0.4% Y/Y
Premium and service revenues · Full Year 2026 Raised $173B – $177B
Apr 28, 2026 $171B – $175B changed to Jul 28, 2026 $173B – $177B
Previous outlook earlier release · from the 8-K filed Apr 28, 2026

Still-open targets the latest release did not restate under the same label.

Investment and other income · 2026 $1.45B
GAAP diluted EPS · 2026 at least $2.37
Adjusted diluted EPS · Annual Guidance December 31, 2026 at least $3.40
Guided vs delivered · last 5 settled
GAAP diluted loss per share full year 2025
guided up to $-12.85
$-13.53 In line
GAAP diluted EPS 2024
guided at least $5.94
$6.31 In line
Total revenues 2023 full year
guided $151B
$154B Beat +2.0%
Revenues full-year 2021
guided $125.2B – $126.4B
$125.98B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+32% Bullish
Price vs 50-day avg
+11% Bullish
RSI (14)
62 Neutral
MACD trend
Positive Bullish
52-week position
97% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $67 › 200d $57 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +170 funds added
Insider flow Distributing
Net -$3.8M over 90 days · 100% sells
Short interest Falling
2.12% of shares out · ▼ -3.9% MoM · 2.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,070 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $32 Now $75 · 97% Range high $76
vs 200-day avg +32% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted diluted EPS non-GAAP $2.51 second quarter of 2026 filing —
Adjusted SG&A expense ratio non-GAAP 6.9% second quarter of 2026 filing —
Cost of service ratio 91.9% the three months ended June 30, 2026 filing —
Effective tax rate on adjusted earnings non-GAAP 26.5% the second quarter of 2026 filing —
HBR 89.6% the three months ended June 30, 2026 filing —
Managed care membership 25.9M second quarter of 2026 filing —
Operating cash flows 3.6B second quarter of 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Healthcare Plans — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CNC
Centene Corp
this stock
$37.02B +81.7% +19.4% 24.8 2.1%
UNH
Unitedhealth Group Inc
$369.18B +24.8% +11.8% 23.5 1.6%
CVS
CVS HEALTH Corp
$113.35B +11.6% +7.8% 10.3 1.4%
ELV
Elevance Health, Inc.
$96.42B +27.3% +12.5% 19.0 2.1%
CI
Cigna Group
$79.09B +9.1% +11.2% 13.3 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,070
% held
97.7%
Net QoQ
-464.9K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
903
View
Short & Settlement
Short Interest Falling
Shares short
10.5M
Days to cover
2.0d
Change
-428.8K sh
View
Short Volume
Short vol %
40%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
65
Value
$4.4K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
37.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$3.8M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Tim Moore
Amount
$100.0K–$250.0K
Traded
Aug 18, 2025
View
Financials
Financials
Revenue (FY)
$194.8B
Net income (FY)
$-6.7B
EPS diluted
$-13.53
View
Buybacks
Authorized
$10.0B
Remaining
$1.8B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 27, 2026
This year
20

Centene Corporation reported third-quarter 2026 GAAP loss per share of $(0.14), adjusted diluted EPS of $0.58 and HBR of 92.7%. It raised 2026 GAAP diluted EPS guidance to greater than $3.46 and adjusted diluted EPS guidance to greater than $5.20.

View
Proposed Sales
Value
$3.8M
Shares
56.5K
Filed
Aug 26, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 27, 2026
View
Investor Relations
Latest news
Ambetter of North Carolina Inc. I…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
CNC +9.1% +9.0% +27.1% +9.2% +81.7%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY +10.8% +12.4% +28.5% +11.3% +73.2%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$10.00B
Spent (derived)
$8.20B
Remaining
$1.80B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1071739 CUSIP 15135B101 13F (30d) 1033 filings 946 filers Visit website Investor relations